574 related articles for article (PubMed ID: 10716680)
21. Genes modulated by histone acetylation as new effectors of butyrate activity.
Della Ragione F; Criniti V; Della Pietra V; Borriello A; Oliva A; Indaco S; Yamamoto T; Zappia V
FEBS Lett; 2001 Jun; 499(3):199-204. PubMed ID: 11423116
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.
Karasawa Y; Okisaka S
Jpn J Ophthalmol; 2004; 48(6):542-51. PubMed ID: 15592778
[TBL] [Abstract][Full Text] [Related]
23. Modulation of complement component (C3 and factor B) biosynthesis by a histone deacetylase inhibitor in human intestinal epithelial cells.
Andoh A; Fujiyama Y; Shimada M; Bamba T
Int J Mol Med; 2000 Jul; 6(1):51-4. PubMed ID: 10851266
[TBL] [Abstract][Full Text] [Related]
24. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
[TBL] [Abstract][Full Text] [Related]
25. Butyrate switches the pattern of chemokine secretion by intestinal epithelial cells through histone acetylation.
Fusunyan RD; Quinn JJ; Fujimoto M; MacDermott RP; Sanderson IR
Mol Med; 1999 Sep; 5(9):631-40. PubMed ID: 10551904
[TBL] [Abstract][Full Text] [Related]
26. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture.
Niki T; Rombouts K; De Bleser P; De Smet K; Rogiers V; Schuppan D; Yoshida M; Gabbiani G; Geerts A
Hepatology; 1999 Mar; 29(3):858-67. PubMed ID: 10051490
[TBL] [Abstract][Full Text] [Related]
27. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells.
Zhang JS; Wang L; Huang H; Nelson M; Smith DI
Genes Chromosomes Cancer; 2001 Feb; 30(2):123-35. PubMed ID: 11135429
[TBL] [Abstract][Full Text] [Related]
28. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
[TBL] [Abstract][Full Text] [Related]
29. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor.
Nakamura M; Saito H; Ebinuma H; Wakabayashi K; Saito Y; Takagi T; Nakamoto N; Ishii H
J Cell Physiol; 2001 Jun; 187(3):392-401. PubMed ID: 11319763
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors promote osteoblast maturation.
Schroeder TM; Westendorf JJ
J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
[TBL] [Abstract][Full Text] [Related]
31. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Ishihara K; Hong J; Zee O; Ohuchi K
Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
[TBL] [Abstract][Full Text] [Related]
32. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
34. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells.
Kobayashi H; Tan EM; Fleming SE
Int J Cancer; 2004 Mar; 109(2):207-13. PubMed ID: 14750171
[TBL] [Abstract][Full Text] [Related]
35. Butyrate Stimulates Histone H3 Acetylation, 8-Isoprostane Production, RANKL Expression, and Regulated Osteoprotegerin Expression/Secretion in MG-63 Osteoblastic Cells.
Chang MC; Chen YJ; Lian YC; Chang BE; Huang CC; Huang WL; Pan YH; Jeng JH
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30562925
[TBL] [Abstract][Full Text] [Related]
36. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
38. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.
Mathew OP; Ranganna K; Yatsu FM
Biomed Pharmacother; 2010 Dec; 64(10):733-40. PubMed ID: 20970954
[TBL] [Abstract][Full Text] [Related]
39. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells.
Archer SY; Meng S; Shei A; Hodin RA
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6791-6. PubMed ID: 9618491
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
